In April 2025, India’s pharmaceutical market expanded by 7.8%, and USV’s Glycomet GP overtook GSK’s Augmentin as the best‑selling brand.

India’s pharmaceutical market recorded sales of ₹19,711 crore in April, marking a 7.8% year‑on‑year rise in value and a 1.3% increase in units sold. This growth edged up from a 7.5% gain in the previous two months but remained below last April’s 9.2% expansion. Despite the slowdown, every major therapy segment contributed to the uptick, aided by several new product launches.

According to Economic Times, a key development in April was the shift in the top‑selling brand rankings. After holding the number‑one spot since early 2024, GSK’s antibiotic Augmentin dropped to second place with net sales of ₹66 crore. It was overtaken by USV’s anti‑diabetic Glycomet GP, which posted ₹74 crore in sales. Himalaya’s LIV.52 claimed third place at ₹72 crore, continuing its role as a physician‑prescribed liver support formulation.

On a moving annual turnover basis, Augmentin remained the leading brand with ₹820 crore in sales as of April 2025. However, its monthly figures showed a steady decline over three months—₹74 crore in January, ₹70 crore in February, and ₹66 crore in April—indicating pressure from competing therapies.

Among therapy areas, cardiac treatments led with ₹2,751 crore in net sales, followed by gastro‑intestinal drugs at ₹2,470 crore, and anti‑infectives at ₹2,169 crore. Anti‑diabetic drugs, including insulins, totaled ₹1,795 crore, while vitamins, minerals, and nutrients reached ₹1,774 crore.

The market’s performance in April suggests a steady, if modest, recovery for Indian pharma. As companies introduce new treatments and competition intensifies, brand rankings may shift further in the coming months. However, the overall growth trend underscores the sector’s resilience amid changing healthcare needs and rising demand for chronic‑care medications.